ECSP20018703A - Inhibidores macrocíclicos de mcl-1 y métodos de uso - Google Patents

Inhibidores macrocíclicos de mcl-1 y métodos de uso

Info

Publication number
ECSP20018703A
ECSP20018703A ECSENADI202018703A ECDI202018703A ECSP20018703A EC SP20018703 A ECSP20018703 A EC SP20018703A EC SENADI202018703 A ECSENADI202018703 A EC SENADI202018703A EC DI202018703 A ECDI202018703 A EC DI202018703A EC SP20018703 A ECSP20018703 A EC SP20018703A
Authority
EC
Ecuador
Prior art keywords
mcl
methods
macrocyclic inhibitors
formula
compounds
Prior art date
Application number
ECSENADI202018703A
Other languages
English (en)
Inventor
Gerard Sullivan
Wilfried Braje
George Doherty
Xilu Wang
Jesse Teske
Michael Wendt
Zhi-Fu Tao
Xiaohong Song
Thomas Penning
Cheng Ji
Frauke Pohlki
Aaron Kunzer
Andreas Kling
Katja Jantos
Andrew Souers
Anthony Mastracchio
Andrew Judd
Chunqui Lai
Original Assignee
Abbvie Inc
Abbvie Deutschland Gmbh Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland Gmbh Co Kg filed Critical Abbvie Inc
Publication of ECSP20018703A publication Critical patent/ECSP20018703A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Abstract

La presente divulgación proporciona compuestos de la Fórmula (I), en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos, que son útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de la Fórmula (I).
ECSENADI202018703A 2017-08-15 2020-03-13 Inhibidores macrocíclicos de mcl-1 y métodos de uso ECSP20018703A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545853P 2017-08-15 2017-08-15
US201762555475P 2017-09-07 2017-09-07
US201862692663P 2018-06-30 2018-06-30

Publications (1)

Publication Number Publication Date
ECSP20018703A true ECSP20018703A (es) 2020-04-22

Family

ID=65362347

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202018703A ECSP20018703A (es) 2017-08-15 2020-03-13 Inhibidores macrocíclicos de mcl-1 y métodos de uso

Country Status (21)

Country Link
US (3) US10676485B2 (es)
EP (2) EP3652184A1 (es)
JP (1) JP2020531433A (es)
KR (1) KR20200041942A (es)
CN (1) CN111818917A (es)
AU (1) AU2018316620A1 (es)
BR (1) BR112020003180A2 (es)
CA (1) CA3073112A1 (es)
CL (2) CL2020000363A1 (es)
CO (1) CO2020002678A2 (es)
CR (1) CR20200124A (es)
EC (1) ECSP20018703A (es)
IL (1) IL272681A (es)
MX (1) MX2020001717A (es)
PH (1) PH12020500327A1 (es)
RU (1) RU2020110517A (es)
SG (2) SG11202001182QA (es)
TW (1) TW201920194A (es)
UA (1) UA126586C2 (es)
UY (1) UY37843A (es)
WO (1) WO2019035911A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200041942A (ko) * 2017-08-15 2020-04-22 애브비 인코포레이티드 거대환식 mcl-1 저해제 및 이의 용도
SI3668512T1 (sl) 2017-08-15 2023-06-30 Agios Pharmaceuticals, Inc. Modulatorji piruvat kinaze in njihova uporaba
AU2018317836A1 (en) * 2017-08-15 2020-03-19 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
EP3668502A4 (en) * 2017-08-15 2021-01-13 AbbVie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
EP3972651A2 (en) 2019-05-20 2022-03-30 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
AU2022291381A1 (en) 2021-06-11 2023-11-30 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
EP4351657A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2276346T3 (pl) * 2008-04-30 2017-07-31 National Health Research Institutes Skondensowane bicykliczne związki pirymidynowe jako inhibitory kinazy aurora
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA3020378A1 (en) 2016-04-22 2017-10-26 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
LT3532067T (lt) 2016-10-28 2022-08-25 Les Laboratoires Servier Liposominė vaisto forma, skirta naudoti gydant vėžį
WO2018126898A1 (zh) 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AU2018317836A1 (en) * 2017-08-15 2020-03-19 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
KR20200041942A (ko) * 2017-08-15 2020-04-22 애브비 인코포레이티드 거대환식 mcl-1 저해제 및 이의 용도
EP3668502A4 (en) * 2017-08-15 2021-01-13 AbbVie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
CN107573360B (zh) 2017-10-27 2019-08-09 都创(上海)医药科技有限公司 一种多靶点小分子化合物s63845的制备方法

Also Published As

Publication number Publication date
KR20200041942A (ko) 2020-04-22
CR20200124A (es) 2020-09-28
SG10202106345VA (en) 2021-07-29
RU2020110517A3 (es) 2022-03-23
EP3652184A4 (en) 2020-05-20
MX2020001717A (es) 2020-10-08
TW201920194A (zh) 2019-06-01
JP2020531433A (ja) 2020-11-05
US20190144465A1 (en) 2019-05-16
EP3988555A1 (en) 2022-04-27
AU2018316620A1 (en) 2020-03-12
CN111818917A (zh) 2020-10-23
CL2020002943A1 (es) 2021-03-12
PH12020500327A1 (en) 2020-10-12
EP3652184A1 (en) 2020-05-20
UY37843A (es) 2019-03-29
US20200325153A1 (en) 2020-10-15
RU2020110517A (ru) 2021-09-16
BR112020003180A2 (pt) 2020-09-15
US20230183261A1 (en) 2023-06-15
IL272681A (en) 2020-03-31
SG11202001182QA (en) 2020-03-30
CA3073112A1 (en) 2019-02-21
CL2020000363A1 (es) 2020-06-12
CO2020002678A2 (es) 2020-08-10
US10676485B2 (en) 2020-06-09
WO2019035911A1 (en) 2019-02-21
UA126586C2 (uk) 2022-11-02

Similar Documents

Publication Publication Date Title
ECSP20018703A (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY37844A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY39630A (es) Inhibidores de bromodominios
CO2022008091A2 (es) Inhibidores de kras g12c
CO2018011064A2 (es) Inhibidores de bromodominios
CL2019001988A1 (es) Compuestos químicos como inhibidores de actividad interleuquina-2.
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
CR20160035A (es) Inhibidores de bromodominios
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2016007440A (es) Inhibidores del bromodominio.
CY1121060T1 (el) Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
UY36123A (es) Derivados de carboxamida
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
TR201813294T4 (tr) N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний